Generic Medicine Info
Indications and Dosage
Adult: 25-50 mg daily, increase if necessary to 75-100 mg. For long-term therapy: 25-50 mg every 2nd or 3rd day.

Adult: 25-50 mg daily alone or in combination with other antihypertensives, alternate-day maintenance dosage may be used.
Severe hepatic or renal impairment; anuria; Addison's disease; hypercalcaemia.
Special Precautions
Fluid and electrolyte disturbances; hepatic cirrhosis; gout. Elderly; severe heart failure; renal impairment. Monitor blood glucose concentrations in patients taking antidiabetics. Lupus erythematosus. Pregnancy and lactation.
Adverse Reactions
Electrolyte imbalance; hyperglycaemia; gout; dry mouth; thirst; weakness; muscle pain and cramp; seizures; hypotension; GI disturbances; anorexia; sialadenitis; headache; impotence; yellow vision; hypersensitivity reactions; cholestatic jaundice; pancreatitis; blood dyscrasias; dizziness; photosensitivity reactions, postural hypotension, paraesthesia.
Drug Interactions
Increased toxicity of digitalis glycosides, allopurinol, tetracyclines. Increased risk of arrhythmia with drugs that prolong the QT interval. Hypotension with other antihypertensives, alcohol, barbiturates, opioids. Increased effects of neuromuscular blockers. Diuretic effects may be antagonised by NSAIDs, corticosteroids, carbenoxolone.
Potentially Fatal: Increased lithium toxicity.
Mechanism of Action: Mefruside reduces the reabsorption of electrolytes from the renal tubules, hence increasing the excretion of sodium and chloride ions and, therefore, of water. It also reduces the glomerular filtration rate.
Onset: 2-4 hrs.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Mefruside from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in